Reprogramming the melanoma tumor immune microenvironment via combinatorial signal 2/3 gene delivery.
Saved in:
| Title: | Reprogramming the melanoma tumor immune microenvironment via combinatorial signal 2/3 gene delivery. |
|---|---|
| Authors: | Luly KM; Center for Translational ImmunoEngineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Translational Therapeutics & Regenerative Engineering Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Department of Biomedical Engineering, Johns Hopkins University, Baltimore, Maryland, USA., Zhou XMM; Center for Translational ImmunoEngineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Surwase SS; Center for Translational ImmunoEngineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Translational Therapeutics & Regenerative Engineering Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Department of Biomedical Engineering, Johns Hopkins University, Baltimore, Maryland, USA., Rocher EE; Center for Translational ImmunoEngineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Translational Therapeutics & Regenerative Engineering Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Department of Biomedical Engineering, Johns Hopkins University, Baltimore, Maryland, USA., Kollings J; Center for Translational ImmunoEngineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Lu C; Center for Translational ImmunoEngineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Will E; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Zhu Q; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Anders RA; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Bloomberg~Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Green JJ; Center for Translational ImmunoEngineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Translational Therapeutics & Regenerative Engineering Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Department of Biomedical Engineering, Johns Hopkins University, Baltimore, Maryland, USA.; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Bloomberg~Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Institute for Nanobiotechnology, Johns Hopkins University, Baltimore, Maryland, USA.; Departments of Neurosurgery and Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Departments of Materials Science & Engineering and Chemical & Biomolecular Engineering, Johns Hopkins University, Baltimore, Maryland, USA., Tzeng SY; Center for Translational ImmunoEngineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Translational Therapeutics & Regenerative Engineering Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Department of Biomedical Engineering, Johns Hopkins University, Baltimore, Maryland, USA., Sunshine JC; Center for Translational ImmunoEngineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA joelsunshine@jhmi.edu.; Translational Therapeutics & Regenerative Engineering Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Department of Biomedical Engineering, Johns Hopkins University, Baltimore, Maryland, USA.; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Bloomberg~Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. |
| Source: | Journal for immunotherapy of cancer [J Immunother Cancer] 2026 Jan 27; Vol. 14 (1). Date of Electronic Publication: 2026 Jan 27. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
